ClinicalTrials.gg

Program

avrukibart

Also written as “ORKA-001”, “ORKA-001 Induction Dose” and “ORKA-001 Maintenance Dose”.

Its studies are mostly in Psoriasis, led by Oruka Therapeutics.

Furthest: phase 2, since Jul 21, 20254 company-led studies, 3 open or runningNext primary completion: May 2030 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Oruka Therapeutics43 open or runningphase 2since Jul 21, 2025Nov 13, 2024May 2030phase 2 · NCT07449702

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 13, 2024First study: phase 1 study in Healthy VolunteersFirst studyNCT06698939 · 24 enrolled · New Zealand
  2. Jul 21, 2025Phase 2 study in Plaque PsoriasisNCT07090330 · 80 enrolled · United States, Canada
  3. Dec 16, 2025Phase 2 study in Plaque PsoriasisNCT07290569 · 160 enrolled · United States, Canada, Germany and more
  4. Feb 26, 2026Phase 2 study in Plaque PsoriasisNCT07449702 · 240 planned · United States, Canada

Ahead

  1. May 2030Primary completion: phase 2 study in Plaque PsoriasisNCT07449702

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07449702Plaque Psoriasis · United States, Canada2RecruitingMay 2030240
NCT07290569Plaque Psoriasis · United States, Canada, Germany and more2Active, not recruitingOct 21, 2026160
NCT07090330Plaque Psoriasis · United States, Canada2Active, not recruitingMar 25, 202680
NCT06698939Healthy Volunteers · New Zealand1CompletedMar 13, 202624

How it is read

Names in the registry

  • “ORKA-001”, 3 entries
  • “ORKA-001 Induction Dose”, 1 entry
  • “ORKA-001 Maintenance Dose”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.
avrukibart (Oruka Therapeutics): development program | ClinicalTrials.gg